Clinical Trial Update: Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating the combination of deucravacitinib with a TNF inhibitor for difficult-to-control psoriatic disease in psoriatic arthritis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Deucravacitinib (deucravacitinib)
• TNF inhibitor (tumor necrosis factor inhibitor)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Psoriatic Arthritis (PsA) | Phase 4 | Status: NOT_YET_RECRUITING